Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is a once-weekly injection licensed in the UK for weight management, but the medicine alone is only part of the story. Clinical trials and NHS guidance are consistent on this point: the strongest results come when Wegovy is taken alongside a reduced-calorie diet and increased physical activity, not instead of them. As a prescription-only medicine, it requires a full clinical assessment before a prescriber can determine whether it is suitable for you. This page walks through the real-world sequence of how Wegovy fits together with the other elements of a weight-management plan, drawing on NHS guidance on semaglutide and the evidence from the STEP clinical programme.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is a common misconception that Wegovy does the work for you, and that diet and exercise become optional once the injections start. It is an understandable assumption (the appetite reduction can feel dramatic in the early weeks) but it is not how the medicine is licensed or how the trials were run.
Wegovy works by activating GLP-1 receptors involved in appetite regulation and the feeling of fullness. It also slows the rate at which food moves out of the stomach, which means you feel satisfied on less. What it does not do is change the nutritional quality of what you eat, maintain muscle mass on its own, or address the habits and patterns that sit underneath eating behaviour. The NHS guidance on obesity treatment is clear that medicines work best as one component of a broader approach, not as a replacement for it.
In the STEP 1 trial, participants using semaglutide 2.4 mg, which you can read more about on our semaglutide page, alongside lifestyle intervention lost an average of around 15% of their body weight over 68 weeks. Participants on placebo with the same lifestyle support lost considerably less. The medicine amplified the effort; it did not substitute for it. Keeping that frame in mind from the start tends to produce better outcomes than treating the injections as a shortcut.
Once Wegovy is prescribed and the dose titration begins (starting at 0.25 mg and progressing, typically in four-weekly steps, up to the 2.4 mg maintenance dose), the reduced appetite that many people notice creates a practical challenge: eating enough of the right things on less overall food.
Protein adequacy matters most. On a lower calorie intake, the body is at risk of losing muscle alongside fat, and adequate protein helps limit that. Hydration also becomes more important because GLP-1 medicines can cause nausea, vomiting and diarrhoea, particularly in the early weeks of a new dose. Fibre from vegetables, pulses and wholegrains supports gut comfort and satiety. Strength-based activity, even modest resistance work at home, helps preserve muscle mass during weight loss. None of this is prescribed by Wegovy's mechanism, it is the part of the picture that you and your clinical team build around the medicine.
For questions about exactly how to structure eating and activity alongside treatment, a prescriber or dietitian is the right person. The NHS Better Health resource at nhs.uk/better-health/lose-weight/ offers a useful foundation while you are getting started.
Wegovy does not exist in a vacuum alongside other medicines or treatments, and a few specific combinations are worth knowing about before you start. This is not a complete list; your prescriber reviews your full medication history at consultation, and that review is where the detail lives.
Women using HRT alongside Wegovy should discuss their HRT route with their doctor. NHS England advises considering transdermal HRT (patches or gels) during treatment with GLP-1 medicines because oral absorption can be affected by the slowed gastric emptying these medicines cause. Similarly, women on oral contraceptives should check whether additional contraceptive precautions are needed, this is particularly relevant for tirzepatide, though your prescriber will confirm what applies to your situation.
People sometimes ask about combining semaglutide with other medicines or supplements for weight management. The question of taking Saxenda and Wegovy together, for instance, comes up occasionally, the short answer is that combining two GLP-1 medicines is not something that is licensed or recommended, and any query about adding other treatments belongs with your prescriber before anything changes. If you are on Ozempic and wondering whether semaglutide products can be used at the same time, our page on whether you can take Ozempic and semaglutide together covers this in detail. The same principle applies to MOTS-c and semaglutide, clinical evidence for that combination is essentially absent, and your prescriber needs to know about any supplements you are taking.
If you are due to have surgery, tell your anaesthetist and surgical team that you are taking Wegovy. GLP-1 medicines slow gastric emptying, which has implications for anaesthesia safety. That conversation should happen before the procedure, not on the day.
The side-effect profile of Wegovy is well characterised. Nausea, constipation, diarrhoea, indigestion and fatigue are most common and tend to peak in the first days after a new dose, then ease. Most people find them manageable and transient. That said, a small number of more serious effects require prompt medical attention.
Severe, persistent stomach pain that spreads to the back (with or without vomiting) needs same-day medical assessment because it can be a sign of pancreatitis. The MHRA highlighted this in a Drug Safety Update in January 2026. Symptoms of gallbladder problems (pain under the right ribs, fever, jaundice) also need prompt attention, as do signs of serious allergic reaction. If you experience low mood or thoughts of self-harm, contact a healthcare professional. You can report any suspected side effect, and any suspect seller of weight-loss medicines, through the MHRA's Yellow Card scheme.
Understanding the full picture of what Wegovy works alongside (and what to watch for) is exactly the kind of conversation that belongs in a clinical consultation. If you are considering treatment with others, our WeGo Together Wegovy programme explains how a shared approach to treatment can support better outcomes. You can also browse the broader range of weight-loss options at our weight-loss overview, or speak to our prescribers directly through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.